NO974964D0 - Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse - Google Patents
Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disseInfo
- Publication number
- NO974964D0 NO974964D0 NO974964A NO974964A NO974964D0 NO 974964 D0 NO974964 D0 NO 974964D0 NO 974964 A NO974964 A NO 974964A NO 974964 A NO974964 A NO 974964A NO 974964 D0 NO974964 D0 NO 974964D0
- Authority
- NO
- Norway
- Prior art keywords
- disease
- alzheimer
- applications
- genetic sequences
- proteins related
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0335—Genetically modified worms
- A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/703—Worms, e.g. Caenorhabdities elegans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/431,048 US6531586B1 (en) | 1995-04-28 | 1995-04-28 | Genetic sequences related to Alzheimer's Disease |
US08/496,841 US6210919B1 (en) | 1995-04-28 | 1995-06-28 | Genetic sequences and proteins related to alzheimer's disease |
US50935995A | 1995-07-31 | 1995-07-31 | |
PCT/CA1996/000263 WO1996034099A2 (en) | 1995-04-28 | 1996-04-29 | Genetic sequences and proteins related to alzheimer's disease, and uses therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
NO974964D0 true NO974964D0 (no) | 1997-10-27 |
NO974964L NO974964L (no) | 1997-12-29 |
Family
ID=27411707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO974964A NO974964L (no) | 1995-04-28 | 1997-10-27 | Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse |
Country Status (19)
Country | Link |
---|---|
US (9) | US5986054A (no) |
EP (2) | EP0826042B1 (no) |
JP (3) | JP4504463B2 (no) |
KR (1) | KR19990008181A (no) |
AT (1) | ATE405645T1 (no) |
AU (1) | AU716307B2 (no) |
BR (1) | BR9608140A (no) |
CA (1) | CA2219214A1 (no) |
CZ (1) | CZ339097A3 (no) |
DE (1) | DE69637649D1 (no) |
DK (1) | DK0826042T3 (no) |
ES (1) | ES2314979T3 (no) |
HU (1) | HUP9801639A3 (no) |
MX (1) | MX9708270A (no) |
NO (1) | NO974964L (no) |
NZ (2) | NZ335945A (no) |
PL (1) | PL185549B1 (no) |
SK (1) | SK145397A3 (no) |
WO (1) | WO1996034099A2 (no) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
ATE305039T1 (de) * | 1995-07-07 | 2005-10-15 | Darwin Molecular Corp | Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist. |
EP0842188A4 (en) * | 1995-07-18 | 2001-06-20 | Univ Washington | GENES S182 MUTANTS |
WO1997007213A2 (en) * | 1995-08-16 | 1997-02-27 | President And Fellows Of Harvard College | Assay for identifying genes causing chromosome non-disjunction |
US6248555B1 (en) * | 1995-08-31 | 2001-06-19 | The General Hospital Corporation | Genetic alterations related to familial alzheimer's disease |
EP0854881A4 (en) * | 1995-09-27 | 2001-10-31 | Univ Columbia | INDICATION OF SEL-12 AND USE THEREFOR |
ZA968898B (en) * | 1995-10-25 | 1998-03-30 | Washington University Of Medic | Method for elucidation and detection of polymorphisms, splice variants and proximal coding mutations using intronic sequences of the mutations Alzheimer's S182 gene. |
JPH10327897A (ja) * | 1996-01-19 | 1998-12-15 | Washington Univ | プレセニリン−1遺伝子の配列を用いる疾患の診断および予後診断 |
WO1997027296A1 (en) * | 1996-01-26 | 1997-07-31 | Hsc Research And Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
AU2541497A (en) * | 1996-04-04 | 1997-10-29 | Institute Of Genomic Research, The | Variant presenilin-2 genes |
EP0811695A3 (en) * | 1996-06-06 | 1998-07-29 | Washington University | Mutant S182(PS-1) genes |
WO1997046678A1 (en) * | 1996-06-06 | 1997-12-11 | Bayer Corporation | Nucleic acids and polypeptides related to presenilin |
EP0814157A3 (en) * | 1996-06-18 | 1998-01-07 | Smithkline Beecham Corporation | Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease |
WO1998001549A2 (en) * | 1996-07-05 | 1998-01-15 | The Governing Council Of The University Of Toronto | Genetic sequences and proteins related to alzheimer's disease, and uses therefor |
JP2001510991A (ja) | 1996-12-02 | 2001-08-07 | ザ ブリガム アンド ウイメンズ ホスピタル,インク. | Alarm関連ペプチドおよび核酸ならびにそれらを用いた診断 |
US6376239B1 (en) * | 1997-04-04 | 2002-04-23 | Elegene Gmbh | DNA molecules comprising a promoter capable of conferring expression of a heterologous DNA sequence |
US6121045A (en) * | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
JP2002505664A (ja) * | 1997-04-24 | 2002-02-19 | ザ ジェネラル ホスピタル コーポレイション | 精製された20kDaのプレセニリン2のC末端フラグメント、およびプレセニリン2のタンパク質分解を阻害する化合物をスクリーニングする方法 |
WO1998051781A1 (en) * | 1997-05-14 | 1998-11-19 | Merck & Co., Inc. | Transgenic animal expressing non-native wild-type and familial alzheimer's disease mutant presenilin 1 protein on native presenilin 1 null background |
ES2128265B1 (es) * | 1997-06-04 | 2000-03-01 | Euroespes S A | Kit genetico para la caracterizacion molecular de la enfermedad de alzheimer. |
US7923216B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US20100081197A1 (en) * | 1997-08-14 | 2010-04-01 | Sylvie Roux | In vivo modulation of neuronal transport |
PT1049712E (pt) * | 1997-08-14 | 2007-04-30 | Pasteur Institut | Proteínas híbridas da toxina do tétano que migram retrogradamente e trans - sinapticamente para o snc |
US6255473B1 (en) * | 1997-08-29 | 2001-07-03 | Duke University | Presenilin-1 gene promoter |
US6284944B1 (en) | 1997-08-29 | 2001-09-04 | Cephalon, Inc, | Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring |
FR2768346B1 (fr) | 1997-09-15 | 2002-04-19 | Fond Jean Dausset Ceph | Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic |
FR2770217B1 (fr) * | 1997-10-24 | 2001-12-07 | Rhone Poulenc Rorer Sa | Peptides capables d'inhiber l'interaction entre les presenilines et le precurseur du peptide b-amyloide et/ou le peptide b-amyloide |
WO1999021886A1 (fr) * | 1997-10-24 | 1999-05-06 | Aventis Pharma S.A. | PEPTIDES CAPABLES D'INHIBER L'INTERACTION ENTRE LES PRESENILINES ET LE PEPTIDE β-AMYLOIDE OU SON PRECURSEUR |
CA2317809A1 (en) * | 1998-01-08 | 1999-07-15 | Daiichi Pharmaceutical Co., Ltd. | Gene mutant animals |
US6383758B1 (en) | 1998-01-09 | 2002-05-07 | The Governing Council Of The University Of Toronto | Alzheimer's related proteins and methods of use |
EP1849477A1 (en) * | 1998-02-25 | 2007-10-31 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by ADP-ribosylating exotoxin |
DE69940906D1 (de) * | 1998-05-21 | 2009-07-02 | Mitsubishi Tanabe Pharma Corp | Verfahren zur untersuchung von krankheiten des zentralen nervensystems und verfahren zum aufsuchen von arzneimitteln |
AR020329A1 (es) * | 1998-07-09 | 2002-05-08 | Boehringer Ingelheim Pharma | UNA SUSTANCIA, EN PARTICULAR UNA RIBOZIMA, CAPAZ DE INHIBIR LA EXPRESION DE PRESENILINA 2, UNA MOLECULA DE DNA RECOMBINANTE QUE CODIFICA DICHA RIBOZIMA, UNVECTOR RECOMBINANTE QUE COMPRENDE EL cDNA CORRESPONDIENTE A DICHA RIBOZIMA, UNA CELULA HOSPEDADORA QUE COMPRENDE DICHO VECTOR RECOMBINANTE, UNA C |
CA2333467A1 (en) * | 1998-07-16 | 2000-01-27 | Incyte Pharmaceuticals, Inc. | Human presenilin-associated protein |
US6797480B1 (en) | 1998-10-05 | 2004-09-28 | University Of Connecticut Health Center | Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents |
US6723557B1 (en) | 1999-01-06 | 2004-04-20 | California Institute Of Technology | Caenorhabditis elegans LOV-1 gene |
US6783982B1 (en) | 1999-02-12 | 2004-08-31 | The Governing Council Of The University Of Toronto | Proteins related to neuronal regeneration and uses thereof |
US6812337B1 (en) | 1999-04-01 | 2004-11-02 | The Governing Council Of The University Of Toronto | Presenilin associated membrane protein and uses thereof |
US6890726B1 (en) | 1999-04-06 | 2005-05-10 | Oklahoma Medical Research Foundation | Method for selecting recombinase variants with altered specificity |
AU4078900A (en) * | 1999-04-06 | 2000-10-23 | Harrington Arthritis Research Center | Methods for tracking the progression of alzheimer's disease and identifying treatments using transgenic mice |
US20030131364A1 (en) * | 1999-04-27 | 2003-07-10 | Karen Duff | Method for producing transgenic animal models with modulated phenotype and animals produced therefrom |
AU6265600A (en) * | 1999-06-22 | 2001-01-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for detection of early-onset alzheimer's disease |
DE60045005D1 (de) | 1999-06-28 | 2010-11-04 | Oklahoma Med Res Found | Inhibitoren des memapsin 2 und ihre verwendung |
US20020049303A1 (en) * | 1999-06-28 | 2002-04-25 | Tang Jordan J. N. | Catalytically active recombinant memapsin and methods of use thereof |
FR2798821B1 (fr) * | 1999-09-27 | 2001-10-26 | Aventis Pharma Sa | Animal transgenique exprimant une forme multi-mutee de la preseniline 1 |
AU2001227960A1 (en) * | 2000-01-21 | 2001-07-31 | University Of Connecticut Health Center | Heat shock/stress protein complexes as vaccines against neurodegenerative disorders |
EP1305634A2 (en) * | 2000-04-03 | 2003-05-02 | Bristol-Myers Squibb Company | Fluorescence assay for gamma-secretase activity and inhibitors |
US20040248092A1 (en) * | 2000-05-26 | 2004-12-09 | Vance Jeffrey M | Methods of screening for parkinsons's disease |
WO2001096361A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Maryland Biotechnology Institute | Method of controlling the binding of calmyrin to presenilin |
US7371920B2 (en) | 2000-06-20 | 2008-05-13 | The Governing Council Of The University Of Toronto | Transgenic mouse model of neurodegenerative disorders |
US20040053251A1 (en) * | 2000-06-30 | 2004-03-18 | Pericak-Vance Margaret A. | Methods of screening for alzheimer's disease |
DE10032709A1 (de) * | 2000-07-07 | 2002-01-24 | Boehringer Ingelheim Pharma | Aspartyl-Protease |
AU2001278919A1 (en) | 2000-07-13 | 2002-01-30 | University Of South Florida | Transgenic animal and methods |
JP2002142765A (ja) * | 2000-07-14 | 2002-05-21 | Tosoh Corp | 新規ゲノム解析法 |
JP2004506429A (ja) * | 2000-08-16 | 2004-03-04 | フリッツェ,マルクス | ヒトの疾患を同定する目的での微生物dna配列の使用 |
WO2002018434A2 (en) * | 2000-09-01 | 2002-03-07 | The Governing Council Of The University Of Toronto | Proteins related to schizophrenia and uses thereof |
US6900367B2 (en) * | 2000-09-29 | 2005-05-31 | Novartis | Transgenic Drosophila melanogaster expressing a β42 in the eye |
US6495335B2 (en) * | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
US20040121947A1 (en) * | 2000-12-28 | 2004-06-24 | Oklahoma Medical Research Foundation | Compounds which inhibit beta-secretase activity and methods of use thereof |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
US20030073608A1 (en) * | 2001-04-10 | 2003-04-17 | Woolf Nancy J. | Process for treating disease |
GB2375771A (en) * | 2001-05-24 | 2002-11-27 | Univ Leeds | Decellularisation of tissue implant material |
JP2003012548A (ja) * | 2001-06-27 | 2003-01-15 | Japan Science & Technology Corp | 医薬組成物 |
IL160396A0 (en) | 2001-08-14 | 2004-07-25 | Sentigen Corp | Nucleic acids and proteins of insect or83b odorant receptor genes and uses thereof |
JP4547152B2 (ja) * | 2001-10-23 | 2010-09-22 | オクラホマ メディカル リサーチ ファウンデーション | β−セクレターゼ阻害剤および使用方法 |
US20060234944A1 (en) * | 2001-10-23 | 2006-10-19 | Oklahoma Medical Reseach Foundation | Beta-secretase inhibitors and methods of use |
ATE361471T1 (de) * | 2001-12-05 | 2007-05-15 | Sense Proteomic Ltd | Protein arrays für allelvarianten und deren verwendung |
EP1469717A4 (en) * | 2001-12-20 | 2007-08-22 | Univ California | TRIPLE TRANSGENIC MOUSE MODEL OF ALZHEIMER'S DISEASE |
US20040014109A1 (en) * | 2002-05-23 | 2004-01-22 | Pericak-Vance Margaret A. | Methods and genes associated with screening assays for age at onset and common neurodegenerative diseases |
US20060259990A1 (en) * | 2002-07-05 | 2006-11-16 | Evotec Neurosciences Gmbh | Diagnostic and therapeutic use of tb2 gene and protein for neurodegenerative diseases |
US20060183117A1 (en) * | 2002-07-08 | 2006-08-17 | Pericak-Vance Margaret A | Screening for alzheimer's disease |
US20040076606A1 (en) * | 2002-09-14 | 2004-04-22 | Ming-Shi Chang | Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding |
US7022481B2 (en) | 2002-12-19 | 2006-04-04 | Rosetta Inpharmatics Llc | Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds |
US20060246437A1 (en) * | 2003-07-11 | 2006-11-02 | Pericak-Vance Margaret A | Genetic susceptibility genes for asthma and atopy and asthma-related and atopic-related phenotypes |
US20060068428A1 (en) * | 2003-11-03 | 2006-03-30 | Duke University | Identification of genetic markers associated with parkinson disease |
US20050191652A1 (en) * | 2003-11-03 | 2005-09-01 | Vance Jeffery M. | Identification of genetic forms of a gene that leads to high risk for parkinson disease |
US20050170392A1 (en) * | 2004-01-30 | 2005-08-04 | Xenoport, Inc. | OAT3 transporters expressed in blood brain barrier cells |
WO2005075684A2 (en) * | 2004-01-30 | 2005-08-18 | Xenoport, Inc. | Use of organic anion transporter b in screens for candidate substrates for crossing the blood brain barrier |
SE0400707D0 (sv) | 2004-03-22 | 2004-03-22 | Bioarctic Neuroscience Ab | Transgenic animal model |
US7790390B2 (en) * | 2004-10-27 | 2010-09-07 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
US7807465B2 (en) * | 2004-10-27 | 2010-10-05 | Duke University | Methods for identifying an individual at increased risk of developing coronary artery disease |
US7833725B2 (en) * | 2005-01-06 | 2010-11-16 | President And Fellows Of Harvard College | Mass spectrometric methods and products |
US20070092449A1 (en) * | 2005-04-05 | 2007-04-26 | Rafael Vazquez-Martinez | Methods for direct visualization of active synapses |
US20070148661A1 (en) * | 2005-07-19 | 2007-06-28 | Duke University | LSAMP Gene Associated With Cardiovascular Disease |
WO2007016144A2 (en) * | 2005-07-29 | 2007-02-08 | Xenoport, Inc. | Octn2 transporters expressed in blood brain barrier cells |
US7700300B2 (en) * | 2005-07-29 | 2010-04-20 | Xenoport, Inc. | Screening of compounds for GAT2 transporter activity |
WO2007016161A2 (en) * | 2005-07-29 | 2007-02-08 | Xenoport, Inc. | Oct3 transporters expressed in blood brain barrier cells |
US7704695B2 (en) * | 2005-07-29 | 2010-04-27 | Xenoport, Inc. | Screening of compounds for BGT1 transporter activity |
WO2007016164A2 (en) * | 2005-07-29 | 2007-02-08 | Xenoport, Inc. | Cat1 transporters expressed in blood brain barrier cells |
CA2618508A1 (en) * | 2005-08-10 | 2007-02-22 | Oklahoma Medical Research Foundation | Truncated memapsin 2 for use for treating alzheimer's disease |
US20090226420A1 (en) * | 2005-11-10 | 2009-09-10 | Elizabeth Hauser | Methods of Determining the Risk of Developing Coronary Artery Disease |
US8852585B2 (en) | 2006-01-30 | 2014-10-07 | Grifols Therapeutics Inc. | Method of treatment and prophylaxis of diseases related to amyloid deposition using IgM |
EP1984396A2 (en) * | 2006-02-06 | 2008-10-29 | Elan Pharmaceuticals Inc. | Inhibitors specific of presenilin-1 and their uses |
US8129334B2 (en) * | 2006-03-31 | 2012-03-06 | The Regents Of The University Of California | Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory |
US7851228B2 (en) * | 2006-03-31 | 2010-12-14 | The Regents Of The University Of California | Methods for screening agents that modulate presenilin activity and A-β production |
AU2007245977A1 (en) * | 2006-05-01 | 2007-11-08 | Aarhus Universitet | An animal model and a method for producing an animal model |
US7771741B2 (en) * | 2006-05-01 | 2010-08-10 | Warsaw Orthopedic, Inc | Demineralized bone matrix devices |
EP2134846B1 (en) * | 2007-03-07 | 2018-08-08 | Aarhus Universitet | Transgenic pig as a model of alzheimer's disease |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012027555A2 (en) | 2010-08-25 | 2012-03-01 | President And Fellows Of Harvard College | Glycated cd59 peptides, their preparation, and uses thereof |
ES2862955T3 (es) | 2010-10-01 | 2021-10-08 | Modernatx Inc | Acidos nucleicos manipulados y métodos de uso de los mismos |
US20140193341A1 (en) * | 2011-01-19 | 2014-07-10 | Asa Abeliovich | Human induced neuronal cells |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
WO2012178183A1 (en) * | 2011-06-24 | 2012-12-27 | Board Of Regents, The University Of Texas System | Human age-related neurodegenerative nematode model and methods |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013052523A1 (en) | 2011-10-03 | 2013-04-11 | modeRNA Therapeutics | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20140343129A1 (en) * | 2011-12-14 | 2014-11-20 | Moderna Therapeutics, Inc. | Modified nucleic acids, and acute care uses thereof |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2833920A2 (en) | 2012-04-02 | 2015-02-11 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
ES2530141B1 (es) * | 2013-08-26 | 2016-01-15 | Juan Carlos GALLAR RUIZ | Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad. |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
AU2016321298A1 (en) | 2015-09-09 | 2018-03-29 | The Trustees Of Columbia University In The City Of New York | Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease |
ES2817910T3 (es) * | 2017-08-04 | 2021-04-08 | Alzheimur 2012 S L | Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer |
EP3796980A4 (en) * | 2018-05-22 | 2022-03-23 | The Brigham & Women's Hospital, Inc. | NEW THERAPY FOR ALZHEIMER'S DISEASE |
KR102584857B1 (ko) * | 2020-09-23 | 2023-10-06 | 재단법인대구경북과학기술원 | 알츠하이머 동물모델 및 이의 용도 |
KR20230009140A (ko) * | 2021-07-08 | 2023-01-17 | 주식회사 엠케이바이오텍 | Human mutant Presenilin-1 발현 인지장애 모델 개의 생산 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4690893A (en) * | 1985-05-03 | 1987-09-01 | Dnax Research Institute Of Molecular And Cellular Biology, Inc. | Hybridoma cell lines producing monoclonal antibodies which specifically bind to mouse interleukin-2 |
DE3752253T2 (de) * | 1986-11-17 | 1999-05-27 | Scios Inc | Rekombiniertes Alzheimer Amyloid-Protein. |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5262332A (en) * | 1989-04-05 | 1993-11-16 | Brigham And Women's Hospital | Diagnostic method for Alzheimer's disease: examination of non-neural tissue |
CA2085127C (en) * | 1990-06-15 | 2002-12-10 | Barbara Cordell | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
JPH05199896A (ja) * | 1990-10-29 | 1993-08-10 | Shinetsu Bio Inc | モノクローナル抗体含有試薬 |
ATE203269T1 (de) * | 1991-03-15 | 2001-08-15 | Hsc Res Dev Ltd Partnership | Genherstellung zur produktion von transgenfisch |
US5297562A (en) * | 1991-04-01 | 1994-03-29 | President And Fellows Of Harvard College | Method for detecting and treating Alzheimer's disease |
NZ242955A (en) * | 1991-06-13 | 1995-01-27 | Ici Plc | Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code |
IL105793A0 (en) * | 1992-05-28 | 1993-09-22 | Lilly Co Eli | Protease and related dna compounds |
JPH07508410A (ja) * | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
US5668006A (en) * | 1992-07-17 | 1997-09-16 | American Cyanamid Company | Somatostatin receptors |
US5449604A (en) * | 1992-10-21 | 1995-09-12 | University Of Washington | Chromosome 14 and familial Alzheimers disease genetic markers and assays |
EP1298436B1 (en) * | 1992-10-26 | 2010-07-14 | Elan Pharmaceuticals, Inc. | Methods for the identification of Beta-amyloid peptide (BAP) release inhibitor compounds |
WO1994023049A2 (en) * | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | The introduction and expression of large genomic sequences in transgenic animals |
US6998467B1 (en) * | 1995-04-28 | 2006-02-14 | The Hospital For Sick Children | Antibody specific for presenilin 1 and method of use thereof |
US6210919B1 (en) * | 1995-04-28 | 2001-04-03 | Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US5986054A (en) | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
US6531586B1 (en) * | 1995-04-28 | 2003-03-11 | The Hospital For Sick Children | Genetic sequences related to Alzheimer's Disease |
ATE305039T1 (de) * | 1995-07-07 | 2005-10-15 | Darwin Molecular Corp | Auf chromosom 1 lokalisiertes gen dessen genprodukt mit der alzheimerschen krankheit assoziiert ist. |
WO1997003086A1 (en) * | 1995-07-13 | 1997-01-30 | University Of South Florida | Early onset alzheimer's disease gene and gene products |
EP0842188A4 (en) * | 1995-07-18 | 2001-06-20 | Univ Washington | GENES S182 MUTANTS |
WO1997027296A1 (en) * | 1996-01-26 | 1997-07-31 | Hsc Research And Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
-
1996
- 1996-01-26 US US08/592,541 patent/US5986054A/en not_active Expired - Lifetime
- 1996-04-29 EP EP96910871A patent/EP0826042B1/en not_active Expired - Lifetime
- 1996-04-29 NZ NZ335945A patent/NZ335945A/xx unknown
- 1996-04-29 ES ES96910871T patent/ES2314979T3/es not_active Expired - Lifetime
- 1996-04-29 CZ CZ973390A patent/CZ339097A3/cs unknown
- 1996-04-29 SK SK1453-97A patent/SK145397A3/sk unknown
- 1996-04-29 BR BR9608140-6A patent/BR9608140A/pt not_active Application Discontinuation
- 1996-04-29 PL PL96323109A patent/PL185549B1/pl unknown
- 1996-04-29 JP JP53205596A patent/JP4504463B2/ja not_active Expired - Lifetime
- 1996-04-29 EP EP08105076A patent/EP2000479A1/en not_active Withdrawn
- 1996-04-29 KR KR1019970707706A patent/KR19990008181A/ko not_active Application Discontinuation
- 1996-04-29 DK DK96910871T patent/DK0826042T3/da active
- 1996-04-29 CA CA002219214A patent/CA2219214A1/en not_active Expired - Lifetime
- 1996-04-29 WO PCT/CA1996/000263 patent/WO1996034099A2/en active IP Right Grant
- 1996-04-29 HU HU9801639A patent/HUP9801639A3/hu unknown
- 1996-04-29 AU AU53940/96A patent/AU716307B2/en not_active Ceased
- 1996-04-29 AT AT96910871T patent/ATE405645T1/de not_active IP Right Cessation
- 1996-04-29 DE DE69637649T patent/DE69637649D1/de not_active Expired - Lifetime
- 1996-04-29 NZ NZ305822A patent/NZ305822A/xx unknown
-
1997
- 1997-10-27 NO NO974964A patent/NO974964L/no not_active Application Discontinuation
- 1997-10-27 MX MX9708270A patent/MX9708270A/es unknown
- 1997-11-10 US US08/967,101 patent/US5840540A/en not_active Expired - Lifetime
-
1998
- 1998-07-29 US US09/124,698 patent/US6117978A/en not_active Expired - Lifetime
- 1998-07-29 US US09/124,523 patent/US6395960B1/en not_active Expired - Lifetime
- 1998-07-31 US US09/127,480 patent/US6194153B1/en not_active Expired - Lifetime
-
2000
- 2000-08-11 US US09/636,796 patent/US6485911B1/en not_active Expired - Lifetime
-
2005
- 2005-02-24 US US11/070,405 patent/US7507798B2/en not_active Expired - Fee Related
-
2007
- 2007-07-27 JP JP2007196770A patent/JP5053746B2/ja not_active Expired - Lifetime
- 2007-08-20 US US11/894,723 patent/US7838247B2/en not_active Expired - Fee Related
-
2008
- 2008-10-28 US US12/259,668 patent/US7846679B2/en not_active Expired - Fee Related
-
2012
- 2012-12-26 JP JP2012282617A patent/JP2013107890A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO974964D0 (no) | Genetiske sekvenser og proteiner som er relatert til Alzheimer's sykdom, og anvendelser av disse | |
WO2004007722A3 (en) | Transgenic animal expressing alzheimer’s tau protein | |
DE69635207D1 (de) | Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist. | |
DE60036297D1 (de) | Bedingtes 'gene trapping'-konstrukt zur unterbrechung von genen | |
WO1998001549A3 (en) | Genetic sequences and proteins related to alzheimer's disease, and uses therefor | |
Wu et al. | Clade-specific genes and the evolutionary origin of novelty; new tools in the toolkit | |
WO2000024768A3 (en) | Genes integrating signal transduction pathways | |
EA199900184A1 (ru) | Протеинкиназы и их применение | |
MXPA02000293A (es) | Isoformas de la amp ciclico fosfodiesterasa y metodos de uso. | |
NZ242955A (en) | Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code | |
NO985280D0 (no) | Anvendelse av en mutasjon i genet for human G-protein 3 subenhet for diagnostisering av sykdommer | |
WO2002018434A3 (en) | Proteins related to schizophrenia and uses thereof | |
WO2002101232A3 (en) | Bace interacting proteins | |
DE60138952D1 (de) | 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen | |
WO2003044170A3 (en) | Cyclic amp phosphodiesterase 4d7 isoforms and methods of use | |
ATE323408T1 (de) | Transgenes tiermodell für neurodegenerative erkrankungen | |
DE50312502D1 (de) | Screeningverfahren zum identifizieren protektiver substanzen für die behandlung neurodegenerativer und/oder ischämischer erkrankungen | |
ATE343632T1 (de) | Mutiertes nurr1 gen | |
SE9701344D0 (sv) | Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method of producing said transgenic animal | |
Haynes | The Rb97D gene encodes a potential RNA-binding protein required for spermatogenesis in Drosophila | |
WO2002026817A3 (en) | 33521, a human guanine nucleotide exchange family member and uses thereof | |
HUP0303286A2 (hu) | Készítmények és eljárások biológiai információ felismerésére és szelektálására | |
ATE257862T1 (de) | Verwendung von calculus | |
WO2003000717A3 (de) | Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen | |
SE9701345D0 (sv) | Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method ofpr oducing said transgenic animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |